Stockscreener 앱 받기
2.45
10.26%
-0.28
시간 외 거래:
2.52
0.07
+2.86%
전일 마감가:
$2.73
열려 있는:
$2.75
하루 거래량:
588.77K
Relative Volume:
0.95
시가총액:
$36.80M
수익:
-
순이익/손실:
$-64.47M
주가수익비율:
-0.3961
EPS:
-6.1852
순현금흐름:
$-52.33M
1주 성능:
-14.93%
1개월 성능:
-18.87%
6개월 성능:
-60.10%
1년 성능:
-85.08%
1일 변동 폭
$2.45
$2.84
1주일 범위
$2.45
$3.04
52주 변동 폭
$2.265
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.45 | 43.56M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Jasper Therapeutics (JSPR) Projected to Post Quarterly Earnings on Tuesday - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc.JSPR - FinancialContent
Layoff Tracker: 60 Biotech Staff Lose Jobs as Poseida, Alltrna Reduce Workforce - BioSpace
What is the risk reward ratio of investing in Jasper Therapeutics Inc. Equity Warrant stockBest Dividend Data Feed Backed By Experts - Jammu Links News
Press Release: Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
What catalysts could drive Jasper Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - Jammu Links News
What are the technical indicators suggesting about Jasper Therapeutics Inc. Equity WarrantStock Strategy Review For Beginners - Jammu Links News
What is the dividend policy of Jasper Therapeutics Inc. Equity Warrant stockGet ahead with breakthrough trading ideas - Jammu Links News
What is Jasper Therapeutics Inc. company’s growth strategyPre Market Picks With High Returns - jammulinksnews.com
Should I hold or sell Jasper Therapeutics Inc. Equity Warrant stock in 2025Top Growth Alerts With Proven Results - Jammu Links News
What makes Jasper Therapeutics Inc. stock price move sharplyPost Market Picks With Low Risk - Jammu Links News
How does Jasper Therapeutics Inc. Equity Warrant generate profit in a changing economySmart Portfolio Signals To Watch Now - jammulinksnews.com
Is Jasper Therapeutics Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert help - Jammu Links News
What is the risk reward ratio of investing in Jasper Therapeutics Inc. stockCapitalize on market trends early - Jammu Links News
What are Jasper Therapeutics Inc. Equity Warrant company’s key revenue driversRapidly expanding wealth - Jammu Links News
Should I hold or sell Jasper Therapeutics Inc. stock in 2025Free Stock Selection - Jammu Links News
Why is Jasper Therapeutics Inc. Equity Warrant stock attracting strong analyst attentionMaximize portfolio value with smart investment plans - Jammu Links News
How does Jasper Therapeutics Inc. compare to its industry peersFree Stock Forecasts For 2025 - jammulinksnews.com
What institutional investors are buying Jasper Therapeutics Inc. stockBuild wealth faster with consistent investment plans - jammulinksnews.com
When is Jasper Therapeutics Inc. stock expected to show significant growthFree Market Dynamics Reports - Jammu Links News
Does Jasper Therapeutics Inc. Equity Warrant stock perform well during market downturnsMassive wealth growth - Jammu Links News
How strong is Jasper Therapeutics Inc. Equity Warrant company’s balance sheetGain access to exclusive stock analysis - Jammu Links News
Is Jasper Therapeutics Inc. Equity Warrant stock overvalued or undervaluedFree Stock Market Return Analysis - jammulinksnews.com
What is the dividend policy of Jasper Therapeutics Inc. stockMaximize gains with professional stock picks - Jammu Links News
Today is July 27 2025 - AInvest
Jasper Therapeutics Inc. Equity Warrant Stock Analysis and ForecastBreakneck growth rates - PrintWeekIndia
When is the best time to buy Jasper Therapeutics Inc. Equity Warrant stockConsistently high yield - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. Equity Warrant stockFree Stock Market Forecast Reports - Autocar Professional
What drives Jasper Therapeutics Inc. stock priceFree Daily Trading Room Entry - Autocar Professional
Is Jasper Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com
Is Jasper Therapeutics Inc. Equity Warrant a good long term investmentFree Stock Market Return Analysis - jammulinksnews.com
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $29.75 Average Target Price from Analysts - Defense World
Jasper Therapeutics Inc. Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What drives Jasper Therapeutics Inc. Equity Warrant stock priceFree Market Volatility Navigation Tips - jammulinksnews.com
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):